Total Payments
$8,450
2024 Payments
$1,330
Companies
58
Transactions
360
Medicare Patients
4,465
Medicare Billing
$2.2M
Payment Breakdown by Category
Food & Beverage$8,101 (95.9%)
Education$310.19 (3.7%)
Other$38.86 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,101 | 355 | 95.9% |
| Education | $310.19 | 4 | 3.7% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $38.86 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $680.69 | 23 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $582.91 | 20 | $0 (2023) |
| Daiichi Sankyo Inc. | $560.55 | 39 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $549.80 | 24 | $0 (2024) |
| PFIZER INC. | $544.81 | 19 | $0 (2024) |
| Merck Sharp & Dohme LLC | $522.46 | 35 | $0 (2024) |
| Incyte Corporation | $381.44 | 16 | $0 (2024) |
| Gilead Sciences, Inc. | $340.23 | 16 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $316.97 | 5 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $270.46 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,330 | 57 | Alexion Pharmaceuticals, Inc. ($236.19) |
| 2023 | $1,355 | 66 | Gilead Sciences, Inc. ($206.55) |
| 2022 | $1,078 | 54 | Daiichi Sankyo Inc. ($162.76) |
| 2021 | $554.02 | 24 | Incyte Corporation ($99.95) |
| 2020 | $1,281 | 49 | Amgen Inc. ($201.85) |
| 2019 | $1,827 | 78 | Amgen Inc. ($323.96) |
| 2018 | $1,026 | 32 | Takeda Pharmaceuticals U.S.A., Inc. ($184.73) |
All Payment Transactions
360 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/29/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $33.35 | General |
| Category: Rare Disease | ||||||
| 12/20/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Oncology | ||||||
| 12/11/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.43 | General |
| 11/21/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: CELLT | ||||||
| 11/02/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $32.56 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $34.50 | General |
| Category: Rare Disease | ||||||
| 10/16/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Rare Disease | ||||||
| 10/15/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $19.42 | General |
| Category: Hematology/Oncology | ||||||
| 10/10/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $2.12 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $34.25 | General |
| Category: Rare Disease | ||||||
| 10/04/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: DESMOID TUMORS | ||||||
| 10/04/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.80 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Oncology | ||||||
| 09/26/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $31.49 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $12.41 | General |
| Category: Iron Deficiency Anemia | ||||||
| 09/20/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $34.25 | General |
| Category: Rare Disease | ||||||
| 09/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.95 | General |
| 09/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 41 | 1,927 | 65,202 | $5.6M | $900,410 |
| 2022 | 38 | 1,879 | 95,977 | $5.5M | $1.1M |
| 2021 | 15 | 659 | 11,211 | $1.1M | $236,312 |
Total Patients
4,465
Total Services
172,390
Medicare Billing
$2.2M
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 83 | 14,163 | $1.0M | $259,455 | 25.1% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 5,800 | $986,608 | $244,846 | 24.8% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 26 | 924 | $1.7M | $71,320 | 4.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 328 | 586 | $205,276 | $56,741 | 27.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 128 | 436 | $208,901 | $50,690 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 87 | 321 | $157,701 | $45,649 | 28.9% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 12 | 1,700 | $351,781 | $38,434 | 10.9% |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | Office | 2023 | 15 | 1,983 | $418,651 | $33,920 | 8.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 27 | 11,310 | $76,343 | $15,408 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 77 | 77 | $46,056 | $13,099 | 28.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 141 | 215 | $50,729 | $11,744 | 23.2% |
| J3490 | Unclassified drugs | Office | 2023 | 29 | 96 | $133,437 | $10,117 | 7.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 99 | 683 | $37,394 | $9,141 | 24.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 44 | 156 | $36,242 | $8,830 | 24.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 130 | 338 | $15,610 | $3,950 | 25.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 96 | $10,990 | $2,850 | 25.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 33 | 104 | $10,402 | $2,501 | 24.0% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 55 | 102 | $9,538 | $2,198 | 23.0% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 49 | 93 | $10,263 | $2,126 | 20.7% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 15 | 23 | $8,247 | $2,007 | 24.3% |
| 36430 | Transfusion of blood or blood products | Office | 2023 | 19 | 45 | $7,086 | $1,586 | 22.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 29 | 61 | $6,321 | $1,517 | 24.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 49 | 226 | $8,528 | $1,439 | 16.9% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 12 | 9,900 | $30,591 | $1,410 | 4.6% |
| 96377 | Application of on-body injector for under skin injection | Office | 2023 | 24 | 71 | $4,594 | $1,131 | 24.6% |
About Farah Nasraty
Farah Nasraty is a Internal Medicine healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2014. The National Provider Identifier (NPI) number assigned to this provider is 1104244813.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Farah Nasraty has received a total of $8,450 in payments from pharmaceutical and medical device companies, with $1,330 received in 2024. These payments were reported across 360 transactions from 58 companies. The most common payment nature is "Food and Beverage" ($8,101).
As a Medicare-enrolled provider, Nasraty has provided services to 4,465 Medicare beneficiaries, totaling 172,390 services with total Medicare billing of $2.2M. Data is available for 3 years (2021–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location La Jolla, CA
- Active Since 03/31/2014
- Last Updated 01/19/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1104244813
Products in Payments
- KEYTRUDA (Biological) $503.91
- IBRANCE (Drug) $491.07
- ULTOMIRIS (Biological) $484.09
- JAKAFI (Drug) $248.26
- Imbruvica (Drug) $236.67
- INJECTAFER (Drug) $217.19
- Trodelvy (Drug) $216.43
- LYNPARZA (Drug) $177.45
- BRUKINSA (Drug) $176.72
- Folotyn (Drug) $162.14
- Enhertu (Drug) $159.73
- Lenvima (Drug) $159.49
- Nerlynx (Drug) $156.86
- TUKYSA (Drug) $146.32
- XPOVIO (Drug) $138.24
- Neulasta (Biological) $137.64
- CALQUENCE (Drug) $118.03
- Tavalisse (Drug) $116.59
- ENHERTU (Drug) $116.51
- NINLARO (Drug) $113.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in La Jolla
Dr. Pam Taub, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Hyong Kim, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. John Rogers, M.d, M.D
Internal Medicine — Payments: $852,868
Internal Medicine $852,868
Rohit Loomba, Md, MD
Internal Medicine — Payments: $849,501
Internal Medicine $849,501
Dr. Fouad Moawad, M.d, M.D
Internal Medicine — Payments: $526,722
Internal Medicine $526,722
Dr. Brian Modena, M.d., Msc, M.D., MSC
Internal Medicine — Payments: $471,187
Internal Medicine $471,187